SC1 Executive Director to speak at our Cambridge 'Science Cities' forum in January 2024
Above: Georgina Rizik, Executive Director, SC1 (Courtesy SC1 / King's Health Partners)
Our popular 'Science Cities' forum returns this January to Newnham College, Cambridge, where the Executive Director of SC1 (London's new life sciences innovation district) Georgina Rizik, will be speaking.
Georgina Rizik is a Global Healthcare and Biotechnology Executive with over 25 years of experience across the private, public and non-profit sectors. Georgina is currently the Executive Director (Chief Executive) at SC1 London Life Sciences Innovation District in south-central London, UK, where she is responsible for setting the vision, strategy and ensuring operational excellence.
SC1 is anchored by King’s College London and supported by the founding partners of three NHS Foundation Trusts (Guy’s and St Thomas, King’s College Hospital, South London and Maudsley), the Guy’s & St Thomas’ Foundation, as well as the Boroughs of Lambeth and Southwark. The mission of SC1 is to Reimagine Innovation and Health Equity.
Georgina brings international commercialization expertise, with a career in Biotechnology (Roche, Novartis & Boehringer Ingelheim) that spans executive leadership roles in global product/portfolio strategy, lifecycle management, business development, launch planning & operations. She had the privilege to contribute to the local and global success for the following transformative Oncology medications: Femara®, Gleevec®, Zometa®, Xeloda®, Herceptin® and Avastin®. An advocate for global health equity, Georgina is also a pioneer in the development of innovative Go To Market strategies for Oncology Biosimilars.
Georgina is a globally minded business leader with strategic and cultural agility having worked in Canada, Switzerland, Germany and the UK with deep knowledge of the Canadian, European, US and international health care systems. In addition, She is engaged in the start-up ecosystem as an Advisor to Health Tech and BioTech companies. She is an Associate at the Creative Destruction Lab (Global Accelerator) and a Strategic Advisor at VoxCell BioInnovation. Experienced in leading teams and building franchises and organizations, these diverse roles have fostered Georgina’s entrepreneurial and collaborative skills, generating global best practices.
Georgina holds a Bachelor of Science in Pharmacy from the University of Toronto. In 2009, she earned her executive MBA from the Kellogg-Schulich EMBA Program (Chicago & Toronto). She is a purpose-driven leader who is passionate about transforming the global approach to the commercialization of innovation in order to drive personalized care and health equity.
King's Health Partners states:
Over three years ago, work began by founders King’s Health Partners, Lambeth and Southwark local authorities and the Guy’s and St Thomas’ Foundation to develop a new life sciences innovation district for London. SC1 is a place-based initiative which will aim to support inclusive growth of the life sciences economy.
The founders established SC1 to harness the opportunities offered in our existing life sciences ecosystem, which contains rich expertise in biopharmaceuticals, medical technology, genomics, diagnostics, digital health and mind and body care. The breadth of our collaboration across partners in south London, coupled with our strength in mental and physical health mean we are uniquely placed to lead innovation in clinical practice and improve health outcomes.
Below: CGI of the London Institute for Healthcare Engineering (LIHE), the first building commissioned for SC1 (Courtesy HLM Architects)
Comentários